Silver Book Fact

Use of a monocolonal antibody with adjuvant chemotherapy in HER2+ individuals with operable cancer was associated with a 33 percent reduction in risk of death.

Romond E, Perez E, Bryant J, Suman V, et al. Tastuzumab Plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer. NEJM. 2005; 353: 1673-84. http://www.nejm.org/doi/full/10.1056/NEJMoa052122

Reference

Title
Tastuzumab Plus Adjuvant Chemotherapy for Operable HER-2 Positive Breast Cancer
Publication
NEJM
Publication Date
2005
Authors
Romond E, Perez E, Bryant J, Suman V, et al.
Pages
1673-84
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • Intensity modulated radiation therapy (IMRT) precisely maps and targets tumors with better tumor control and fewer side effects than other forms of radiation. In one study, IMRT increased the success…  
  • According to the Pharmaceutical Research and Manufacturers of America, a medicine in development targets CA125, a surface protein, or antigen, that is released in excess quantities by some ovarian cancers.…  
  • The overall five-year survival rate for men with prostate cancer is 99 percent—up from 43 percent in 1975.  
  • For women age 40 or older, timely mammograms could reduce breast cancer mortality by about 16%–compared to those who are not screened.  
  • Baseline lung cancer screening would lead to more than 130,000 additional survivors in 2012.